Previous 10 | Next 10 |
Introduction Strongbridge Biopharma ( SBBP ) is a commercial stage biopharmaceuticals company engaged in the development and commercialization of therapies for rare diseases with significant unmet needs. The company currently markets two drugs (Macrilen and Keveysis) and has another (Recor...
DUBLIN, Ireland and TREVOSE, Pa., July 01, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
DUBLIN, Ireland and TREVOSE, Pa., June 12, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced t...
Market Assessment Strongbridge Biopharma ( SBBP ) is a small-cap ($161 million) commercial-stage biopharmaceutical company developing innovative therapies for rare diseases affecting the neuromuscular and endocrine systems (i.e., acromegaly and Cushing’s syndrome). Commercial products...
The following slide deck was published by Strongbridge Biopharma plc in conjunction with this Read more ...
Scott Wilhoit Promoted to Chief Commercial Officer Marcy Nanus Appointed Vice President of Corporate Affairs DUBLIN, Ireland and TREVOSE, Pa., June 04, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused o...
AEterna Zentaris ( AEZS ) recently reported an abysmal Q1 earnings report that revealed the company only received $0.04 million in royalty revenue, which was a bit of a headscratcher seeing that the expected revenue was over $4 million. One would think there would be a strong sell-off when a c...
DUBLIN, Ireland and TREVOSE, Pa., May 30, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced th...
~ Results Demonstrate Long-term Treatment with KEVEYIS is Efficacious and Provides Durable Reduction in Attack Frequency and Severity in Patients with PPP ~ DUBLIN, Ireland and TREVOSE, Pa., May 09, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercia...
Gainers: ARCA biopharma (NASDAQ: ABIO ) +37% . MFC Bancorp (NYSE: MFCB ) +32% . Enphase Energy (NASDAQ: ENPH ) +29% . Precipio (NASDAQ: PRPO ) +25% . Nu Skin Enterprises (NYSE: NUS ) +25% . Nanometrics Incorporated (NASDAQ: NANO ) +22% . Qumu Corporation (NASDAQ: QUMU ) +22% ....
News, Short Squeeze, Breakout and More Instantly...
Strongbridge Biopharma plc Company Name:
SBBP Stock Symbol:
NASDAQ Market:
Strongbridge Biopharma plc Website:
DUBLIN, Ireland and TREVOSE, Pa., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “Company” or “Strongbridge”) today announced that the High Court of Ireland (the "Court") has approved the previously announced proposed a...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that the High Court of Ireland (the “ Court ”) has set the dat...
DUBLIN, Ireland and TREVOSE, Pa., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc (NASDAQ: SBBP) (the “ Company ” or “ Strongbridge ”) today announced that its shareholders have voted to approve the previously announced proposed ac...